28A-1100728
TW I857553、 PCT專利申請中
The limitations in treating mucopolysaccahridosis I (MPS I) have motivated us to explore strategies for improvement. In this work, the IdoA-typed C-glycosides as α-l -Iduronidase (IDUA) modulators have been developed. These compounds exhibited promising potency to modulate IDUA, as demonstrated in enzyme-based assays. Structural modifications around the potent scaffolds were systematically investigated to fine-tune their biological activity. In addition, our data showed that 17 and 19b could stabilize the exogenous recombinant IDUA and thus facilitate its cellular uptake in MPS I cell lines. These compounds, specifically 17 and 19b, have the potential to function as small-molecule IDUA stabilizers, protecting the MPS I protein drug from denaturation during systemic circulation. Notably, a co-administration therapy consisting of a recombinant enzyme and its protein stabilizer has been approved by the FDA in 2023 for Pompe disease. This success endorses our co-administration strategy with IDUA stabilizers to improve the current enzyme replacement therapy for MPS I. We hope our invention can effectively reduce the requisite dosage of MPS I protein drug, and prolong its enzyme activity for improved therapeutic efficacy.
- First-in-class small molecules for the potential treatment of MPS I
- These small molecules can stabilize the current protein drug to reduce the cost of enzyme replacement therapy for MPS-I
- Specific IDUA enzyme stabilizers
- If the small molecules can be applied alone, it is useful for neuro-developing MPS I diseases
- The current most potent reversible inhibitor against IDUA
- Applications or treatment related to the inhibition/stabilization toward IDUA
- The small molecules we developed can stabilize IDUA enzyme, displaying promising therapeutic potential for treating MPS I, one of the lysosomal storage diseases
- A cost-cutting strategy for the current treatment toward MPS I
Cheng, Wei-Chieh
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Novel Small molecules for the treatment of GAG accumulation disorders